Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Terrell A. Patterson is active.

Publication


Featured researches published by Terrell A. Patterson.


Neuropharmacology | 2007

CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity

Judith A. Siuciak; Douglas S. Chapin; Sheryl A. McCarthy; Victor Guanowsky; Janice A. Brown; Phoebe Chiang; Ravi B. Marala; Terrell A. Patterson; Patricia A. Seymour; Andrew G. Swick; Philip A. Iredale

CP-809,101 is a potent, functionally selective 5-HT(2C) agonist that displays approximately 100% efficacy in vitro. The aim of the present studies was to assess the efficacy of a selective 5-HT(2C) agonist in animal models predictive of antipsychotic-like efficacy and side-effect liability. Similar to currently available antipsychotic drugs, CP-809,101 dose-dependently inhibited conditioned avoidance responding (CAR, ED(50)=4.8 mg/kg, sc). The efficacy of CP-809,101 in CAR was completely antagonized by the concurrent administration of the 5-HT(2C) receptor antagonist, SB-224,282. CP-809,101 antagonized both PCP- and d-amphetamine-induced hyperactivity with ED(50) values of 2.4 and 2.9 mg/kg (sc), respectively and also reversed an apomorphine induced-deficit in prepulse inhibition. At doses up to 56 mg/kg, CP-809,101 did not produce catalepsy. Thus, the present results demonstrate that the 5-HT(2C) agonist, CP-809,101, has a pharmacological profile similar to that of the atypical antipsychotics with low extrapyramidal symptom liability. CP-809,101 was inactive in two animal models of antidepressant-like activity, the forced swim test and learned helplessness. However, CP-809,101 was active in novel object recognition, an animal model of cognitive function. These data suggest that 5-HT(2C) agonists may be a novel approach in the treatment of psychosis as well as for the improvement of cognitive dysfunction associated with schizophrenia.


American Journal of Physiology-regulatory Integrative and Comparative Physiology | 1999

Sodium depletion and aldosterone decrease dopamine transporter activity in nucleus accumbens but not striatum

Mitchell F. Roitman; Terrell A. Patterson; Randall R. Sakai; Ilene L. Bernstein; Dianne P. Figlewicz

Motivated behaviors, including sodium (Na) appetite, are correlated with increased dopamine (DA) transmission in the nucleus accumbens (NAc). DA transporter (DAT) modulation affects DA transmission and may play a role in motivated behaviors. In vivo Na depletion, which reliably induces Na appetite, was correlated with robust decreases in DA uptake via the DAT in the rat NAc with rotating disk electrode voltammetry [1,277 ± 162 vs. 575 ± 89 pmol ⋅ s-1 ⋅ g-1; Vmax of transport for control vs. Na-depleted tissue]. Plasma aldosterone (Aldo) levels increase after in vivo Na depletion and contribute to Na appetite. Decreased DAT activity in the NAc was observed after in vitro Aldo treatment (428 ± 28 vs. 300 ± 25 pmol ⋅ s-1 ⋅ g-1). Neither treatment affected DAT activity in the striatum. These results suggest that a direct action of Aldo is one possible mechanism by which Na depletion induces a reduction in DAT activity in the NAc. Reduced DAT activity may play a role in generating increased NAc DA transmission during Na appetite, which may underlie the motivating properties of Na for the Na-depleted rat.


American Journal of Physiology-gastrointestinal and Liver Physiology | 2013

Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans

Benjamin S. Maciejewski; Jennifer L. LaPerle; Danny Chen; Avijit Ghosh; William J. Zavadoski; Thomas S. McDonald; Tara B. Manion; Dawn Mather; Terrell A. Patterson; Maya Hanna; Steven Watkins; E. Michael Gibbs; Roberto A. Calle; Claire M. Steppan

Alterations in fat metabolism, in particular elevated plasma concentrations of free fatty acids and triglycerides (TG), have been implicated in the pathogenesis of Type 2 diabetes, obesity, and cardiovascular disease. Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1), a member of the large family of membrane-bound O-acyltransferases, catalyzes the final step in triacylglycerol formation. In the intestine, DGAT1 is one of the acyltransferases responsible for the reesterficiation of dietary TG. Following a single dose of a selective pharmacological inhibitor of DGAT1, PF-04620110, a dose-dependent inhibition of TG and vitamin A absorption postprandially was demonstrated in rodents and human subjects. In C57/BL6J mice, acute DGAT1 inhibition alters the temporal and spatial pattern of dietary lipid absorption. To understand the impact of DGAT1 inhibition on enterocyte lipid metabolism, lipomic profiling was performed in rat intestine and plasma as well as human plasma. DGAT1 inhibition causes an enrichment of polyunsaturated fatty acids within the TG class of lipids. This pharmacological intervention gives us insight as to the role of DGAT1 in human dietary lipid absorption.


Bioorganic & Medicinal Chemistry Letters | 2010

Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity

Kevin K.-C. Liu; Peter Cornelius; Terrell A. Patterson; Yuan Zeng; Stephanie Santucci; Elizabeth Tomlinson; Colleen P. Gibbons; Tristan S. Maurer; Ravi B. Marala; Janice A. Brown; Jimmy Kong; Eunsun Lee; Wendy Werner; Zane Wenzel; Chandra Vage

Based on our original pyrazine hit, CP-0809101, novel conformationally-restricted 5HT2c receptor agonists with 2-piperazin-azaindane scaffold were designed. Synthesis and structure-activity relationship (SAR) studies are described with emphasis on optimization of the selectivity against 5HT2a and 5HT2b receptors with excellent 2c potency. Orally-active and selective compounds were identified with dose-responsive in vivo efficacy in our pre-clinical food intake model.


Regulatory Peptides | 2005

Food intake in rhesus monkeys following central administration of orexins.

Jon J. Ramsey; Joseph W. Kemnitz; Wendy Newton; Kevork Hagopian; Terrell A. Patterson; Andrew G. Swick

Orexin A has been reported to stimulate food intake in rats while orexin B does not. The purpose of this study was to determine the role of orexin A or orexin B administration on food intake in adult, male rhesus monkeys. Food intake was measured at 2 and 8 h after the morning feeding following central injections of vehicle, orexin A (10, or 20 microg) or orexin B (10, 30, or 100 microg). When compared to vehicle injections, the 10 and 20 microg doses of orexin A decreased food intake at 2 h post-dose by 45% and 64%, respectively. Eight-hour food intake was decreased at only the 20 microg orexin A dose. Orexin B at all doses and time points did not alter food intake when compared to vehicle. These results indicate that orexin A exhibits anorectic activity while orexin B does not affect food intake in the rhesus monkey.


Bioorganic & Medicinal Chemistry Letters | 2010

Orally active and brain permeable proline amides as highly selective 5HT2c agonists for the treatment of obesity.

Kevin K.-C. Liu; Bruce Allen Lefker; Mark A. Dombroski; Phoebe Chiang; Peter Cornelius; Terrell A. Patterson; Yuan Zeng; Stephanie Santucci; Elizabeth Tomlinson; Colleen P. Gibbons; Ravi B. Marala; Janice A. Brown; Jimmy Kong; Eunsun Lee; Wendy Werner; Zane Wenzel; Craig Giragossian; Hou Chen; Steven B. Coffey

Brain-penetrable proline amides were developed as 5HT2c agonists with more than 1000-fold binding selectivity against 5HT2b receptor. After medicinal chemistry optimization and SAR studies, orally active proline amides with robust efficacy in a rodent food intake inhibition model were uncovered.


Bioorganic & Medicinal Chemistry Letters | 2012

Discovery and evaluation of spirocyclic derivatives as antagonists of the neuropeptide Y5 receptor.

Michael Fichtner; Eunsun Lee; Elizabeth Tomlinson; Dennis O. Scott; Peter Cornelius; Terrell A. Patterson; Philip A. Carpino

A novel series of spirocyclic derivatives was synthesized and evaluated as NPY Y5R antagonists for the treatment of obesity. Cis and trans analogs 7a and 8a were equipotent in a Y5R binding assay (K(i)s ≤ 1 nM) and displayed good stability in human and rat liver microsome preparations. Compound 7a failed to demonstrate weight loss activity in a diet-induced obese (DIO) rat model at unbound drug levels in the brain that exceeded the Y5R K(i) value by 25-fold over a 24-h time-period.


PLOS ONE | 2016

Evaluation of a Mathematical Model of Rat Body Weight Regulation in Application to Caloric Restriction and Drug Treatment Studies

Jangir Selimkhanov; W. Clayton Thompson; Terrell A. Patterson; John R. Hadcock; Dennis O. Scott; Tristan S. Maurer; Cynthia J. Musante

The purpose of this work is to develop a mathematical model of energy balance and body weight regulation that can predict species-specific response to common pre-clinical interventions. To this end, we evaluate the ability of a previously published mathematical model of mouse metabolism to describe changes in body weight and body composition in rats in response to two short-term interventions. First, we adapt the model to describe body weight and composition changes in Sprague-Dawley rats by fitting to data previously collected from a 26-day caloric restriction study. The calibrated model is subsequently used to describe changes in rat body weight and composition in a 23-day cannabinoid receptor 1 antagonist (CB1Ra) study. While the model describes body weight data well, it fails to replicate body composition changes with CB1Ra treatment. Evaluation of a key model assumption about deposition of fat and fat-free masses shows a limitation of the model in short-term studies due to the constraint placed on the relative change in body composition components. We demonstrate that the model can be modified to overcome this limitation, and propose additional measurements to further test the proposed model predictions. These findings illustrate how mathematical models can be used to support drug discovery and development by identifying key knowledge gaps and aiding in the design of additional experiments to further our understanding of disease-relevant and species-specific physiology.


Bioorganic & Medicinal Chemistry Letters | 2003

Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TRβ subtype-selective thyromimetics

Robert L. Dow; Steven R. Schneider; Ernest S. Paight; Richard F. Hank; Phoebe Chiang; Peter Cornelius; Eunsun Lee; William P. Newsome; Andrew G. Swick; Josephine Spitzer; Diane M. Hargrove; Terrell A. Patterson; Jayvardhan Pandit; Boris A. Chrunyk; Peter K. LeMotte; Dennis E. Danley; Michele H. Rosner; Mark Ammirati; Samuel P. Simons; Gayle K. Schulte; Bonnie Frances Tate; Paul DaSilva-Jardine


Journal of Medicinal Chemistry | 2003

In vitro and in vivo characterization of 3-{2-[6-(2-tert-butoxyethoxy)pyridin-3-yl]-1H-imidazol-4-yl}benzonitrile hydrochloride salt, a potent and selective NPY5 receptor antagonist

Richard L. Elliott; Robert M. Oliver; Marlys Hammond; Terrell A. Patterson; Li She; Diane M. Hargrove; Kelly A. Martin; Tristan S. Maurer; J. Cory Kalvass; Bradley Paul Morgan; Paul DaSilva-Jardine; Ralph W. Stevenson; Christine M. Mack; James V. Cassella

Collaboration


Dive into the Terrell A. Patterson's collaboration.

Researchain Logo
Decentralizing Knowledge